Support making RiG more international!
Click here to start the surveySupport making "Research in Germany" more international! Your expertise and commitment are essential for advancing the promotion of the German research landscape. We invite you to participate in our online survey and share your valuable insights after your website visit.
Possibly win up to €100 in rewards by participating in the follow-up survey. Duration: 7-10 minutes
Cancer Research
Germany is one of the leading actors in the pursuit of researching, fighting and ultimately annihilating cancer. On this page, we want to give you more information on the German research landscape in the field of cancer research and highlight some players and institutions that work towards this goal. Learn more about who does cancer research in Germany, where you can get the right funding for your work in this field and get in touch with the right people that can help you join the fight against cancer in Germany.
Who does cancer research in Germany?
Cancer research in Germany is conducted at universities and also at non-university research institutions. Almost all universities host a cancer research section. The spectrum ranges from small monothematic working groups to large interdisciplinary departments and covers a variety of topics from traditional areas to new explorative research fields.
For a comprehensive overview, please take a look at our brochure “Research in Germany - Cancer Research”:
Research in Germany - Cancer Research (2022, 32 pages)
Are you interested in pursuing your PhD or getting cooperation partners in the field of Cancer Research in Germany? We invite you to explore the many opportunities available to you in Germany. This brochure provides students, early career researchers and partners from abroad with information to find places of interest and potential cooperation partners in their specific field.
On top of this, there is a lot more to discover: the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) funds a multitude of individual projects in the area of cancer research. These individual grants outweigh the research consortia that are listed in the brochure both in number and in overall funding volume. The online database GEPRIS provides information on all DFG-funded research projects. Use this online database to find out which scientists in Germany work in your field of expertise!
Research institutions focusing on cancer research
Here are some examples of outstanding institutions and projects that focus on cancer research, both at non-university and university-based research institutions:
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is the largest biomedical research institute in Germany and a member of the Helmholtz Association of National Research Centers. In over 90 divisions and research groups, more than 3,100 employees, of which more than 1,300 are scientists, are investigating the mechanisms of cancer, are identifying cancer risk factors and are trying to find strategies to prevent people from getting cancer. They are developing novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. (Source: www.dkfz.de)
Talent management and career development at the DKFZ plays a central role in maintaining excellence. Structured education of graduate students is provided by the DKFZ International PhD Program and, together with the DKFZ International Postdoc Program and an established Career Service, our training programs prepare junior scientists for their next career step inside or outside of academia. The new DKFZ Clinician Scientist Program fosters innovative translational research by strengthening the research profile of clinician scientists.
The DKFZ offers various job and career opportunities for cancer researchers of all career levels. Current job offers can be accessed directly on dkfz.de or here.
Contact
German Cancer Research Center
Im Neuenheimer Feld 280
69120 Heidelberg
The global number of patients suffering from cancer will continue to rise in the next decades, especially due to demographic changes and an ageing population. Despite significant advancements in cancer screening and early diagnosis, around one quarter of all patients are diagnosed with advanced cancer stages, the majority of which cannot be offered a curative therapeutic option. While the number of innovative cancer therapies (molecularly targeted therapies, novel cytotoxic drugs, immunotherapies) is continuously rising, long term therapeutic success is often hampered by the development of therapy resistance. In order to lay the foundation for the development of improved future cancer therapies, scientists of the Cluster of Excellence 2180 "Image-guided and Functionally Instructed Tumor Therapies" (iFIT) are studying fundamental tumor biological processes in solid tumors. The unique iFIT approach is based on a highly intertwined and boundless research program comprising Tübingen´s three internationally competitive research areas “Functionally Instructed Molecular Therapies”, “Immunotherapies” and “Molecular and Functional Multiparametric Imaging”.
Functionally Instructed Molecular Therapies
Scientists from this research area take advantage of advanced platforms for high throughput functional genetic screening (in particular in vivo screens) to pinpoint new vulnerabilities in therapy resistant solid tumors. A major focus also lies on screens to identify potential targets in T-cells or tumor cells, which upon inhibition via small molecules increase the therapeutic efficacy of cancer immunotherapies. Proprietary small molecule inhibitors against prioritized therapeutic targets are developed in close collaboration with the Tübingen Center for Academic Drug Discovery and Development (TüCAD2).
Immunotherapies
How can innovative immunotherapies help to activate our defense system against tumor cells? Scientists from the research area “Immunotherapies” have performed pioneering work by elucidating the recognition mechanisms of T-cells. They recognize peptides, which are presented on special cell surface molecules. These peptides enable T-cells to detect pathological changes in the cells. Based on this, the concept of individualized cancer peptide vaccination was developed.
Molecular and Functional Multiparametric Imaging
How can multiparametric imaging be further developed to achieve a quantifiable visualization of functional, molecular and immunological mechanisms of tumors? Scientists from the research area “Molecular and Functional Multiparametric Imaging” are dedicated to develop novel-specific tracers and MR biomarkers to image immune cells in vivo as well as cellular stress and related metabolic changes of tumor cells during tumor development and after therapy.
Spokesperson and participating institutions
Spokesperson of the cluster is the oncologist Professor Lars Zender, Medical Director of the Department of Medical Oncology and Pneumology of the University Hospital Tübingen. Co-spokespersons are Professor Bernd Pichler, Director of the Werner Siemens Imaging Center at the University of Tübingen, and Professor Hans-Georg Rammensee, director of the Institute of Immunology at Tübingen University. Further participating institutions are the Max Planck Institute for Intelligent Systems, the Max Planck Institute for Biological Cybernetics, the Natural and Medical Sciences Institute at the University of Tübingen, the Margarete Fischer Bosch Institute for Clinical Pharmacology and the German Cancer Consortium.
Contact
iFIT Cluster of Excellence
iFIToffice@med.uni-tuebingen.de
Röntgenweg 11
72076 Tübingen
Germany
Fraunhofer ITEM is one of 76 institutions of the Fraunhofer-Gesellschaft, Europe's leading organization for applied research. Headquartered in Hannover (Germany) and with additional facilities in Braunschweig and Regensburg, the institute aims to protect man from health hazards in our industrialized world and to contribute to the development of novel therapeutic approaches.
The Fraunhofer ITEM division in Regensburg is dedicated to Personalized Tumor Therapy and has a special expertise in the isolation and characterization of disseminated or circulating cancer cells. Circulating tumor cells (CTC) are isolated, for example, by taking simple blood samples (referred to as “liquid biopsy”), whereas disseminated cancer cells (DCC) can be isolated from lymph node tissue or bone marrow. These rare cells are subject to in-house, advanced next-generation multi-omics sequencing technologies and bioinformatic data analysis to reliably analyze the comprehensive genetic information at the single-cell level. Further expertise includes the analysis of cell-free, tumor-derived blood components (circulating tumor DNA, microvesicles) and innovative tissue-based analytical methods (tissue biopsy). Additionally, supported by a large clinical network, Fraunhofer ITEM in Regensburg is developing workflows for rare-cell expansion and has already established a multitude of in-vitro/in-vivo models based on DCC or CTC from various tumor entities. These preclinical models are used for high-throughput screening of substances and RNAi/CRISPR libraries to identify active agents and targets to gain a better functional understanding of DCC and CTC biology and of their response to therapy. This provides new opportunities not only for molecular diagnostics in precision oncology, but also for the investigation of pathophysiological processes in rare driver cells.
In addition, ex-vivo models developed by the institute’s Division of Preclinical Pharmacology and Toxicology in Hannover offer a novel opportunity to study early stages of metastasis and primary human tumors. Precision-cut tissue slice (PCTS) systems either from tumor tissue or peripheral organs co-cultured with tumor cells enable the investigation of human tissue-derived immune reactions, for instance key events of immune tolerance to tumor cells or early colonization events in metastasis. This facilitates testing of treatments such as gene therapy, checkpoint inhibitors or cell therapeutics with regard to their mode of action, targeting, efficacy and toxicity in an organotypic human setting.
The particular value of such a model is based on 1) human background, addressing the complexity of the appropriated microenvironment, 2) patient-specificity of the tumor cells in order to reflect tumor heterogeneity, 3) immune competence to assess the tolerance-inducing mechanisms, and 4) applicability of molecular and cellular manipulation and analysis tools.
Research on personalized tumor therapy is one of several key topics at Fraunhofer ITEM. Focusing on lung and inhalation, the institute’s divisions in Hannover and Braunschweig have pooled their expertise in three business units:
In the business unit Drug Development, we develop and test novel medications against respiratory diseases (including lung cancer). Scientific expertise covers manufacturing of biologics such as therapeutic antibodies, preclinical and clinical development.
The business unit Chemical Safety is dedicated to determining the risks from potentially harmful substances. Scientific expertise includes toxicology testing, exposure assessment, analytical methods, regulatory research and risk assessment.
The business unit Translational Biomedical Engineering offers many years of experience in the development of medical devices – specifically neural implants and medical aerosolizers – including testing and testing scenarios, safety and risk assessment.
All business units offer regulatory support.
Numerous test systems are available, including in-vitro, ex-vivo and in-vivo. Studies can be performed in compliance with GXP regulations.
Personalized Tumor Therapy
Fraunhofer ITEM – pioneers for sustainable health
Funding for international cancer researchers in Germany
Whether you are a young international researcher looking for a scholarship, an early career researcher wanting to pursue a PhD in the field of cancer research at a German graduate school, or a more experienced researcher who wants to start a collaboration with a German partner – the right funding programme can help you with your next career step. Finding the right programme can make all the difference.
For an overview of funding opportunities, please see our brochure about funding programmes for international researchers:
Funding your research in Germany (2023-24, 80 pages)
A selection of funding programmes for German and foreign academics run by the most important research funding institutions. Target group: international students, graduates, post-docs and academics interested in a research stay in Germany.
Most of the funding programmes that are included in the brochure, are offered by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), the German Academic Exchange Service (DAAD) and the Alexander von Humboldt Foundation.
You can find more detailed descriptions of these organizations when looking for in-depth information on your PhD, Postdoc and Advanced Research in Germany.
Get in touch with us!
To help you navigate through the German cancer research landscape and find the right funding programme for your needs, we invite you to get in touch with us!
Deutsche Forschungsgemeinschaft (DFG, German Research Foundation):
Dr. Stefan Thiel stefan.thiel@dfg.de, Department II, Life Sciences
Dr. Anke Deggerich anke.deggerich@dfg.de, Department II, Life Sciences
Ms. Bettina Schuffert bettina.schuffert@dfg.de, DFG Office North America
iFIT Cluster of Excellence "Image-guided and Functionally Instructed Tumor Therapies":
Ms. Eva Enzinger ifitoffice@med.uni-tuebingen.de